380,000 vaccinated so far, no serious adverse events, says health ministry

Two deaths were reported in Uttar Pradesh and Karnataka, one not linked to jab, the other yet to be investigated

Topics
Coronavirus Vaccine | Health Ministry | health workers in India

Ruchika Chitravanshi  |  New Delhi 

coronavirus vaccine
An Adverse Event Following Immunization (AEFI) is any unexpected medical occurrence which follows immunisation

Three days into the Covid-19 vaccination drive, almost 400,000 healthcare workers have received the shot in 7,700 sessions across the country, according to the Even as the numbers have failed to match the government expectation, some 580 adverse events and two deaths reported in and kept the authorities busy all of Monday, trying to give out an assurance that the vaccines were safe.

For the death of a 52-year-old hospital staff from Moradabad, the vaccine connection was ruled out after a post-mortem. He died a day after receiving the Covishield vaccine. In the second case of a 43-year-old man from Bellary dying after getting vaccinated, post-mortem findings are yet to be out. The vaccine he took has not been revealed. Doctors found pockets of pus and an enlarged heart in the post mortem, which led to a cardiopulmonary disease and caused the death of the Moradabad health worker. In the second case, the cause of death was found to be anterior wall infarction with cardiopulmonary failure.

The exact details will be established after a post mortem study is done.

“He was brought dead to the hospital,” the chief medical officer at Moradabad government hospital said.

Coronavirus, vaccine, covid, drugs, clinical trials

Dr Devi Prasad Shetty, chairman & executive director, Narayana Health, being adminstered a dose of Covid vaccine, in Bengaluru, on Monday | Photo: PTI

An Adverse Event Following Immunization (AEFI) could be any unexpected medical occurrence after vaccination. It may or may not be related to the vaccine or vaccination process.

The turnout of healthcare workers has been lower than expected over fears linked to the safety of vaccines. The data as of 5 pm showed that had vaccinated maximum number of beneficiaries at 36,888, followed by Odisha at 22,579.

chart

Of the seven cases of hospitalization, two were discharged while five were kept under observation. One person fainting was being monitored at Max Hospital in Delhi. The reported case of AEFI in Uttarakhand is stable and under observation at AIIMS, Rishikesh. The rest were under observation in various hospitals in Chhattisgarh and

The has stated that no serious adverse event has occurred yet due to the vaccine.

Most states have picked four days in a week to hold Covid vaccine sessions.

India plans to vaccinate 30 million healthcare and frontline workers initially. Around 300 million — including senior citizens with comorbidities — are expected to be vaccinated by the next phase.

In the first lot, of India has supplied 11 million doses of Covishield and another 45 million doses are likely to be taken by the government soon. has supplied lower number of doses of Covaxin, which got the regulator's approval under the third phase clinical trial.

Besides supply side issues, the is also trying to fix the problems related to the CO-Win software, which is being used to track the vaccine delivery. Many states have raised concern that the digital platform was slow, causing delay in uploading beneficiary lists. As a result, states have been managing the data, contacting beneficiaries manually and later uploading the data online.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Mon, January 18 2021. 20:29 IST
RECOMMENDED FOR YOU